{"id":"NCT01067105","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","officialTitle":"A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2010-02-11","resultsPosted":"2012-06-11","lastUpdate":"2012-06-13"},"enrollment":824,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"ciclesonide HFA 160 μg","otherNames":[]}],"arms":[{"label":"ciclesonide","type":"EXPERIMENTAL"}],"summary":"6-month safety extension study in subjects who have completed Study 060-633 (NCT00953147). Evaluating the long-term safety of ciclesonide HFA nasal aerosol 160 μg administered once-daily in patients with Perennial Allergic Rhinitis.","primaryOutcome":{"measure":"Percentage of Subjects Experiencing Adverse Events (AEs)","timeFrame":"Weeks 1-26","effectByArm":[{"arm":"Ciclesonide","deltaMin":51.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":824},"commonTop":["Upper respiratory tract infection","Epistaxis","Headache","Sinusitis","Nasopharyngitis"]}}